Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Sail Biomedicines, formerly, Senda Biosciences

Organization & Developments: Senda Biosciences

Parents

*Platform combines circular RNA technology and programmable nanoparticles to unlock drugs by leveraging eRNA, artificial intelligence, and nanoparticle deployment
2025: Flagship's Sail Biomedicines sends staff packing for 2nd time this year
Flagship Pioneering founded Senda Biosciences to create a new field of medicine, leveraging insights from the naturally occurring exchange of molecules between human and non-human cells in the human ecosystem.
Senda Biosciences is a first-in-category company in the tradition of other Flagship Pioneering therapeutics companies such as Moderna, Laronde, and Tessera Therapeutics.
The Senda platform comprehensively deconstructs the codes provided by nature to harness them for therapeutic purposes
The unique properties of these medicines include tissue targeting beyond the liver, repeatable dosing with sustained expression, tunable in vivo immunomodulation, and multiple routes of administration – creating new frontiers for mRNA therapeutics and vaccines, with further potential to transform the gene editing and protein-based therapy landscapes as well.